- Home
- ADVM vs DTIL Comparison
ADVM vs DTIL Comparison
Compare ADVM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- DTIL
- Stock Information
- Founded
- ADVM 2006
- DTIL 2006
- Country
- ADVM United States
- DTIL United States
- Employees
- ADVM N/A
- DTIL N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- DTIL Health Care
- Exchange
- ADVM Nasdaq
- DTIL Nasdaq
- Market Cap
- ADVM 66.3M
- DTIL 55.3M
- IPO Year
- ADVM 2014
- DTIL 2019
- Fundamental
- Price
- ADVM $3.02
- DTIL $4.61
- Analyst Decision
- ADVM Strong Buy
- DTIL Strong Buy
- Analyst Count
- ADVM 4
- DTIL 2
- Target Price
- ADVM $19.75
- DTIL $47.00
- AVG Volume (30 Days)
- ADVM 84.1K
- DTIL 78.0K
- Earning Date
- ADVM 11-03-2025
- DTIL 11-03-2025
- Dividend Yield
- ADVM N/A
- DTIL N/A
- EPS Growth
- ADVM N/A
- DTIL N/A
- EPS
- ADVM N/A
- DTIL N/A
- Revenue
- ADVM $1,000,000.00
- DTIL $1,261,000.00
- Revenue This Year
- ADVM $1,836.70
- DTIL N/A
- Revenue Next Year
- ADVM N/A
- DTIL $135.19
- P/E Ratio
- ADVM N/A
- DTIL N/A
- Revenue Growth
- ADVM N/A
- DTIL N/A
- 52 Week Low
- ADVM $1.78
- DTIL $3.61
- 52 Week High
- ADVM $8.56
- DTIL $10.71
- Technical
- Relative Strength Index (RSI)
- ADVM 50.02
- DTIL 40.75
- Support Level
- ADVM $2.93
- DTIL $4.86
- Resistance Level
- ADVM $3.59
- DTIL $5.17
- Average True Range (ATR)
- ADVM 0.22
- DTIL 0.24
- MACD
- ADVM -0.02
- DTIL -0.03
- Stochastic Oscillator
- ADVM 13.64
- DTIL 16.18
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.